Can low T3 signaling raise LDL particle burden?

Thyroid hormone status is a primary endocrine determinant of systemic lipid metabolism, directly modulating circulating atherogenic lipoproteins.

Mechanistic pathways

• Direct genomic transcription: Active thyroid hormone ($T_3$) binds to thyroid hormone receptor $\beta 1$ ($\text{TR}\beta 1$) in hepatocytes. This complex directly targets thyroid response elements (TREs) on the low-density lipoprotein receptor (LDLR) promoter—specifically at the $-612$ bp and $-156$ bp regions—to drive receptor gene expression. In states of low $T_3$ signaling, the loss of this direct activation reduces LDLR transcription.
• SREBP-2 pathway modulation: Beyond direct genomic action, low $T_3$ levels downregulate the transcription and nuclear processing of sterol regulatory element-binding protein 2 (SREBP-2). This blunts the hepatic cholesterol-sensing feedback loop, preventing SREBP-2 from binding the sterol regulatory element (SRE) to rescue falling LDLR expression.

Physiological clearance kinetics

• Impaired clearance rate: Because LDLR is the primary pathway for internalizing apolipoprotein B-100 (ApoB-100) on LDL particles, diminished receptor activity significantly reduces the fractional catabolic rate (FCR) of circulating LDL.
• Atherogenic particle accumulation: A lower FCR prolongs the residence time of LDL particles in the plasma. Metabolic tracer studies confirm that this clearance failure, rather than lipoprotein overproduction, drives the accumulation of circulating LDL particle number (LDL-P) and total ApoB, elevating systemic particle burden.

Bottom line

• Low $T_3$ signaling directly impairs hepatic LDL receptor activity via both $\text{TR}\beta 1$-TRE genomic pathways and indirect SREBP-2 feedback mechanisms. This down-regulation reduces the fractional clearance rate of ApoB-100 particles, prolonging their circulation and raising systemic LDL-P burden.